IL2 and cancer: Previous studies have shown that due to the short serum half-life, the administration of higher doses of IL-2 will be required for efficient antitumor activity, which will lead to unacceptable toxicity in treated cancer patients (Konrad et al. 1990; Tang and Harding 2019).